Showing 281 - 300 results of 4,547 for search '"Journal for ImmunoTherapy of Cancer"', query time: 0.18s Refine Results
  1. 281
    89 Non-invasive imaging of tumor-infiltrating B lymphocytes in a triple negative breast cancer model using anti-CD20 immunoPET

    89 Non-invasive imaging of tumor-infiltrating B lymphocytes in a triple negative breast cancer model using anti-CD20 immunoPET by Sunidhi Jaiswal, Saad N Ahmed, Felix B Salazar, Masoud Farshbaf, Bao Y Chen, Jennifer Chean, Kirstin A Zettlitz

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  2. 282
    818 Reheating the glioblastoma tumor microenvironment by direct conversion of glioblastoma to induced dendritic cell-like antigen presenting cells

    818 Reheating the glioblastoma tumor microenvironment by direct conversion of glioblastoma to induced dendritic cell-like antigen presenting cells by David Tran, Mathew Sebastian, Dan Jin, Dongjiang Chen, Son Le, Tianyi Liu

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  3. 283
    Correction: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

    Correction: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

    Published 2021-06-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  4. 284
    PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion

    PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion by Lei Yu, Yan Wang, Jin Wang, Zhiqiang Liu, Feng Liu, Han Zhao, Yi Tao, Jian-Qing Mi, Nan Xu, Wanyan Ouyang, Shi-Wei Jin, Wei-Yang Liu, Liuqingqing Zhang, Liqing Kang, Yuanfang Liu

    Published 2024-04-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  5. 285
    Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity

    Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity by Lei Huang, Andrew L Mellor, Henrique Lemos, Rong Ou, Caroline McCardle, Yijun Lin, Jessica Calver, Jack Minett, Ahmed Chadli

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  6. 286
    Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service

    Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service by Michael Manos, Patrick Ott, Osama Rahma, F Stephen Hodi, Shilpa Grover, Peter Bowling, Jian Ni, Nicole R LeBoeuf, Osama Abu-Shawer, Prabhsimranjot Singh, Eric Yenulevich, Amanda Brito, Raja-Elie E Abdulnour, Joseph Jacobson

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  7. 287
    Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology

    Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology by Na Liu, Lei Chen, Wei Jiang, Yu Zhang, Yu-Pei Chen, Ya-Qin Wang, Yan-Ping Mao, Ying-Qing Li, Shuo-Yu Xu, Xiao-Min Li, Qing-Mei He, Shi-Wei He, Xiao-Jing Yang, Yuan Lei, Yin Zhao, Jing-Ping Yun, Yingqin Li

    Published 2020-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  8. 288
    Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12

    Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12 by Stephen J Russell, Haifei Jiang, Rebecca Nace, Talia Fernandez Carrasco, Lianwen Zhang, Kah Whye Peng

    Published 2024-03-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  9. 289
    Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

    Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma by Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis

    Published 2016-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  10. 290
    Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse

    Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse by Chao Ma, Weiqiang Chen, Lunan Liu, Zhuoyu Zhang, Matthew T Witkowski, Iannis Aifantis, Saba Ghassemi

    Published 2022-12-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  11. 291
    131 Evaluating the presence and temporal distribution of immune components in matrigel-based sarcoma and gallbladder cancer patient derived tumoroids (PDTs) that have intact tumor microenvironment

    131 Evaluating the presence and temporal distribution of immune components in matrigel-based sarcoma and gallbladder cancer patient derived tumoroids (PDTs) that have intact tumor... by Damieanus Ochola, Huckie Del Mundo, Bhuvanesh Dave, Preethi Samuel

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  12. 292
    Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

    Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy by Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff

    Published 2024-04-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  13. 293
    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

    694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in sol... by Bart Neyns, Bart Ilsen, Jens Tijtgat, Frederik Vandenbroucke, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Steven Raemaeckers, Selma Ben Mustapha, Jens Van Loon, Lore Decoster, Mark De Ridder

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  14. 294
    1239 Major adverse cardiovascular events (MACE) in patients with melanoma receiving immune checkpoint inhibitors

    1239 Major adverse cardiovascular events (MACE) in patients with melanoma receiving immune checkpoint inhibitors by Bo Zhao, Maria E Suarez-Almazor, Hui Zhao, Jennifer McQuade, Nicolas Palaskas, Anita Deswal, Juan I Ruiz

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  15. 295
    Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

    Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer by Simon Smith, Woong-Yang Park, Kyoung-Mee Kim, Jeeyun Lee, Jung Yong Hong, Seung Tae Kim, Won Ki Kang, Emma Dean, Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Peter G S Mortimer, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai

    Published 2022-07-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  16. 296
    498 ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response

    498 ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response by Rui Gao, Jing Gao, Chunnian Wang, Dawei Sun, Hongtao Lu, Wenqiang Lu, Quan Qiu, Jingfeng Yu, Zeyu Liu, Hongping Zhou

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  17. 297
    51 Tissue-based spatial analysis of DLBCL tumor microenvironment using multiplex immunofluorescence AQUA® (Automated Quantitative Analyses) algorithms

    51 Tissue-based spatial analysis of DLBCL tumor microenvironment using multiplex immunofluorescence AQUA® (Automated Quantitative Analyses) algorithms by Xun Li, Jennifer Bordeaux, Jaspreet Kaur, Sarah Choi, Lisa Adams, Jimmie Lim, Sophia Kekchidou

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  18. 298
    832 Overcome solid tumor immunosuppression for T cells-mediated cancer elimination

    832 Overcome solid tumor immunosuppression for T cells-mediated cancer elimination by Yuan Liu, Lei Shi, Zhen Bian, Harry Stylli, Jane Zen

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  19. 299
    Correlation of safety and efficacy of atezolizumab therapy across indications

    Correlation of safety and efficacy of atezolizumab therapy across indications by Jarushka Naidoo, Guru Sonpavde, Mark A Socinski, Rajat Mohindra, Corey Carter, Laurent Essioux, Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Javier Puente, Jose Vicente Cardona

    Published 2024-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  20. 300
    Use of artificial intelligence chatbots in clinical management of immune-related adverse events

    Use of artificial intelligence chatbots in clinical management of immune-related adverse events by Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan

    Published 2024-05-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article

Search Tools: